NanoVibronix, Inc. (NAOV)

US — Healthcare Sector
Peers: BJDX  VERO  BBLG  MOVE  AMIX  HSCS  CNSP  GRI  ACON  NDRA 

Automate Your Wheel Strategy on NAOV

With Tiblio's Option Bot, you can configure your own wheel strategy including NAOV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol NAOV
  • Rev/Share 5.4947
  • Book/Share 118.8629
  • PB 0.0263
  • Debt/Equity 0.003
  • CurrentRatio 0.8601
  • ROIC -0.1699

 

  • MktCap 2494344.0
  • FreeCF/Share -20.3806
  • PFCF -0.3426
  • PE -0.313
  • Debt/Assets 0.0023
  • DivYield 0
  • ROE -0.1198

 

  • Rating
  • Score
  • Recommendation
  • P/E Score
  • DCF Score
  • P/B Score
  • D/E Score

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

ENvue Medical, Formerly NanoVibronix, UroShield® Kit Secures Reimbursement in the UK
NAOV
Published: December 18, 2025 by: GlobeNewsWire
Sentiment: Neutral

Peak Medical, ENvue's Exclusive Distributor in UK, Places Significant Order after Reimbursement Decision, Projecting Future Market Demand for UroShield® Kit Peak Medical, ENvue's Exclusive Distributor in UK, Places Significant Order after Reimbursement Decision, Projecting Future Market Demand for UroShield® Kit

Read More
image for news ENvue Medical, Formerly NanoVibronix, UroShield® Kit Secures Reimbursement in the UK
NanoVibronix Announces Results from UroShield™ Case Series
NAOV
Published: May 12, 2025 by: Business Wire
Sentiment: Neutral

TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company”), a medical technology company specializing in therapeutic devices, today announced findings from a recent retrospective case series evaluating the clinical impact and patient experience of the UroShield™ system. The case series, conducted between September 2023 and January 2025 by researchers at University Hospitals Coventry and Warwickshire Partnership NHS, assessed a small group of patients who used the UroShield.

Read More
image for news NanoVibronix Announces Results from UroShield™ Case Series

About NanoVibronix, Inc. (NAOV)

  • IPO Date 2015-05-28
  • Website https://www.nanovibronix.com
  • Industry Medical - Devices
  • CEO Doron Robert Besser
  • Employees 31
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.